Startups
Renovion is developing a new nebulizer therapy to treat lung mucus and improve lung function for patients of lung transplant, non-cystic fibrosis bronchiectasis (NCFBE), non-tuberculous mycobacteria-lung disease (NTM-LD), and Tracheostomy.
Overview
Location
United States, Virginia
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 17, 2017 | Durham-based Renovion Raises More Than $1.8 Million | A North Carolina-based pharmaceutical company raised over $1.8 million in equity, according to a filing with the Securities and Exchange Commission. Durham-based Renovion Inc. filed a Form D signed by Daniel Copeland, Joseph Davis, R. McCoy... |
| RENOVION | “Developing a new nebulizer theraphy to treat lung mucus and improve lung function for patients of lung transplant, non-cystic fibrosis bronchiectasis (NCFBE), non-tuberculous mycobacteria-lung disease (NTM-LD), and Tracheostomy.” |
Reviews 0
FAQ about Renovion
What has the press written about Renovion?
Parsers VC has collected 3 articles mentioning Renovion, among them “Durham-based Renovion Raises More Than $1.8 Million” (Jan 17, 2017) and “RENOVION”.
Is Renovion still active?
Yes, Renovion is active; its latest activity on Parsers VC dates from Feb 29, 2024.